Idorsia’s treatment for insomnia disorder wins the inaugural Prix Galien Bridges Award in the ‘Best Biotechnology & Pharmaceutical Product’ category

Idorsia’s dual orexin receptor antagonist, the first and only drug of its kind approved in Europe for the treatment of ...

Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...